Shanghai Junshi Biosciences Co., Ltd.

SEHK:1877 Voorraadrapport

Marktkapitalisatie: HK$28.3b

Shanghai Junshi Biosciences Toekomstige groei

Future criteriumcontroles 2/6

Shanghai Junshi Biosciences zal naar verwachting groeien in winst en omzet met respectievelijk 37.6% en 30% per jaar. De winst per aandeel zal naar verwachting groeien met 39.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -27.5% zijn.

Belangrijke informatie

37.6%

Groei van de winst

39.4%

Groei van de winst per aandeel

Biotechs winstgroei42.6%
Inkomstengroei30.0%
Toekomstig rendement op eigen vermogen-27.5%
Dekking van analisten

Low

Laatst bijgewerkt22 Oct 2024

Recente toekomstige groei-updates

Recent updates

Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Price Is Right But Growth Is Lacking After Shares Rocket 35%

Oct 14
Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Price Is Right But Growth Is Lacking After Shares Rocket 35%

Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?

Sep 30
Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?

Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Revenues Are Not Doing Enough For Some Investors

Aug 29
Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Revenues Are Not Doing Enough For Some Investors

Shanghai Junshi Biosciences (HKG:1877) Has Debt But No Earnings; Should You Worry?

Jun 28
Shanghai Junshi Biosciences (HKG:1877) Has Debt But No Earnings; Should You Worry?

Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Fly 27% But Investors Aren't Buying For Growth

May 06
Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Fly 27% But Investors Aren't Buying For Growth

Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?

Mar 22
Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?

Risks Still Elevated At These Prices As Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Dive 29%

Jan 26
Risks Still Elevated At These Prices As Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Dive 29%

Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?

Dec 17
Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?

Is Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Trading At A 38% Discount?

Nov 20
Is Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Trading At A 38% Discount?

Health Check: How Prudently Does Shanghai Junshi Biosciences (HKG:1877) Use Debt?

Sep 05
Health Check: How Prudently Does Shanghai Junshi Biosciences (HKG:1877) Use Debt?

Revenues Not Telling The Story For Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

May 22
Revenues Not Telling The Story For Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Could Be 35% Below Their Intrinsic Value Estimate

May 01
Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Could Be 35% Below Their Intrinsic Value Estimate

A Look At The Intrinsic Value Of Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

Jan 16
A Look At The Intrinsic Value Of Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

Some Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Analysts Just Made A Major Cut To Next Year's Estimates

Nov 03
Some Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Analysts Just Made A Major Cut To Next Year's Estimates

Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?

Oct 12
Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?

Winst- en omzetgroeiprognoses

SEHK:1877 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20263,310-647-1,256-8823
12/31/20252,556-1,114-1,595-1,0973
12/31/20241,777-1,460-1,904-1,3963
9/30/20241,787-1,803-2,303-1,454N/A
6/30/20241,619-1,931-2,671-1,645N/A
3/31/20241,628-2,023-2,581-1,661N/A
12/31/20231,503-2,283-2,838-2,005N/A
9/30/20231,222-2,200-3,037-2,323N/A
6/30/20231,177-2,473-2,988-2,544N/A
3/31/20231,079-2,535-3,489-3,067N/A
12/31/20221,453-2,388-2,170-1,776N/A
9/30/20222,525-1,924-1,708-1,182N/A
6/30/20222,856-1,643-1,663-1,109N/A
3/31/20223,039-1,495-1,207-434N/A
12/31/20214,025-721-1,507-605N/A
9/30/20213,302-945-1,769-902N/A
6/30/20213,134-1,060-1,735-892N/A
3/31/20213,038-1,062-1,398-703N/A
12/31/20201,595-1,669-2,037-1,456N/A
9/30/20201,259-1,418-1,945-1,365N/A
6/30/20201,041-1,056-1,699-1,032N/A
3/31/2020868-600-1,876-1,120N/A
12/31/2019775-747-2,042-1,179N/A
9/30/2019528-732-1,927-1,092N/A
6/30/2019310-735-1,704-913N/A
3/31/201979-992-1,555-824N/A
12/31/20181-717-1,060-511N/A
9/30/2018N/A-516-877-387N/A
6/30/2018N/A-439N/A-443N/A
3/31/20180-347N/A-364N/A
12/31/20171-321N/A-347N/A
9/30/20179-279N/A-348N/A
6/30/20175-246N/A-275N/A
3/31/20179-191N/A-243N/A
12/31/20164-131N/A-185N/A
9/30/20164-109N/A-169N/A
6/30/20162-83N/A-139N/A
3/31/20162-71N/A-110N/A
12/31/20153-58N/A-82N/A
9/30/20155-43N/A-66N/A
6/30/20157-27N/A-50N/A
3/31/20156-26N/A-45N/A
12/31/20146-25N/A-39N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat 1877 de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat 1877 de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat 1877 de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van 1877 ( 30% per jaar) zal naar verwachting sneller groeien dan de markt Hong Kong ( 7.8% per jaar).

Hoge groei-inkomsten: De omzet van 1877 ( 30% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat 1877 binnen 3 jaar verliesgevend zal zijn.


Ontdek groeibedrijven